Global Preeclampsia Laboratory Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Preeclampsia Laboratory Testing Market Analysis

The preeclampsia laboratory testing market is experiencing significant growth, driven by advancements in diagnostic technologies and an increasing demand for early detection of preeclampsia. Preeclampsia, a pregnancy complication characterized by high blood pressure and organ damage, can have serious consequences for both the mother and the baby. As awareness of this condition grows, there is an increasing need for reliable and accurate laboratory tests to identify it early, improving the chances of effective management and treatment.

The market consists of various types of tests, including blood and urine tests, aimed at detecting markers of preeclampsia. Over time, there has been a shift toward more sophisticated testing methods, with newer tests offering improved sensitivity and faster results. These advancements contribute to the market's expansion, as healthcare providers seek more efficient ways to diagnose and monitor preeclampsia.

In addition, the market is seeing a rise in the adoption of point-of-care testing devices, which provide rapid results and can be used in various healthcare settings, from hospitals to outpatient clinics. The demand for these portable and easy-to-use diagnostic tools is expected to further fuel market growth.

Overall, the preeclampsia laboratory testing market is poised for continued growth as innovations in diagnostic tools enhance the ability to detect and manage preeclampsia more effectively, improving maternal and fetal health outcomes.

Preeclampsia Laboratory Testing Market Size

The Preeclampsia Laboratory Testing market size was valued at USD 16.32 billion in 2024 and is projected to reach USD 31.37 billion by 2032, with a CAGR of 8.51% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Preeclampsia Laboratory Testing Market Trends

 “Increasing preference for non-invasive diagnostic methods”

The preeclampsia laboratory testing market is seeing several key trends that are shaping its development and adoption. One prominent trend is the increasing preference for non-invasive diagnostic methods. The increasing preference for non-invasive diagnostic methods in the preeclampsia laboratory testing market reflects a growing emphasis on patient comfort and safety. Traditional diagnostic methods often involve more invasive procedures, such as blood pressure measurements or taking multiple blood samples, which can be uncomfortable for expectant mothers. Non-invasive testing, on the other hand, aims to minimize physical intervention, making the diagnostic process less stressful and more user-friendly.

Non-invasive methods in preeclampsia detection primarily focus on using easily obtainable biological samples, such as urine or blood, to analyze biomarkers associated with the condition. For instance, urine tests that measure protein levels, or blood tests that assess certain biomarkers, provide valuable insights into whether a pregnant woman is at risk of developing preeclampsia without the need for invasive procedures.

Another significant aspect of non-invasive testing is the development of wearable devices and mobile technologies. These devices allow continuous monitoring of vital signs such as blood pressure, which is a key indicator of preeclampsia, without requiring frequent hospital visits. The use of such technologies makes it easier for healthcare providers to monitor patients at home, reducing the need for invasive testing and enabling early detection of any changes in the patient’s condition.

Incorporating non-invasive diagnostic methods not only enhances patient experience but also encourages greater compliance with regular testing, ultimately leading to improved outcomes in managing preeclampsia.

Report Scope Preeclampsia Laboratory Testing Market Segmentation

Preeclampsia Laboratory Testing Market Definition

Preeclampsia laboratory testing refers to a set of diagnostic procedures and tests designed to detect and monitor preeclampsia, a pregnancy complication characterized by high blood pressure and potential organ damage, most commonly affecting the kidneys and liver. These tests aim to identify early signs of preeclampsia in pregnant women, allowing healthcare providers to intervene before the condition becomes severe and leads to serious health risks for both the mother and the baby.

The laboratory tests used in preeclampsia detection typically involve the analysis of urine and blood samples. Urine tests are commonly used to measure protein levels, as excessive protein in the urine (proteinuria) is a key indicator of preeclampsia. Blood tests are often employed to assess liver and kidney function and to measure markers such as platelet count, uric acid levels, and specific biomarkers that may signal the presence of the condition.

Preeclampsia Laboratory Testing Market Dynamics

Drivers

• Increasing prevalence of preeclampsia

The rising number of pregnant women diagnosed with preeclampsia is a major driver for the laboratory testing market. Preeclampsia affects about 5-8% of pregnancies globally, and with the increasing awareness of maternal health, more women are being screened and diagnosed. As the condition can lead to severe complications for both the mother and baby, early detection through laboratory tests becomes critical. The growing recognition of the importance of early intervention to avoid complications, such as organ damage and premature birth, is pushing the demand for advanced diagnostic tools. This, in turn, is driving the expansion of the preeclampsia laboratory testing market.

• Technological advancements in diagnostic tools

The continuous advancement of diagnostic technologies plays a significant role in the market's growth. Newer, more sophisticated laboratory tests and devices, such as point-of-care testing and more accurate biomarker-based diagnostics, are improving early detection and monitoring of preeclampsia. These innovations are enabling faster, non-invasive, and more reliable testing, which is increasing the adoption of preeclampsia laboratory tests. Healthcare providers are more inclined to use these advanced tools to enhance patient care and reduce the risk of severe complications associated with undiagnosed preeclampsia. As a result, these technological advancements help drive market growth by improving both diagnostic efficiency and patient outcomes.

Opportunities

• Rising demand for non-invasive testing

As healthcare systems strive for safer, less intrusive ways to monitor pregnancy, there is a growing opportunity for the development and adoption of non-invasive laboratory testing methods for preeclampsia. Non-invasive tests, such as urine-based and blood-based biomarkers, reduce the physical stress and discomfort on pregnant women, making it easier to implement regular monitoring. These methods align with the increasing focus on patient-centred care, which emphasizes comfort and safety. The growing preference for non-invasive tests represents a valuable opportunity for companies to innovate and offer safer diagnostic options that cater to both healthcare providers and patients, thereby driving market growth.

• Expanding use of wearable devices for monitoring

Wearable health technologies are becoming increasingly popular in maternal care, presenting an opportunity for the preeclampsia laboratory testing market to incorporate continuous monitoring solutions. Devices that track vital signs, such as blood pressure and heart rate, can help detect early signs of preeclampsia without the need for frequent hospital visits. The integration of wearables with laboratory testing and patient monitoring systems presents a lucrative opportunity for companies to develop hybrid solutions that offer both continuous real-time data and advanced diagnostic testing. This could not only enhance early detection but also improve patient outcomes by allowing for more timely interventions.

Restraints/Challenges

• High costs of advanced diagnostic tests

Despite the growing adoption of advanced diagnostic technologies for preeclampsia, one of the major restraints is the high cost associated with some of these tests. Specialized equipment and the use of novel biomarkers or non-invasive testing methods may be expensive for healthcare facilities, particularly in low-resource settings. In addition, high test costs may limit access for certain patient populations, resulting in disparities in diagnosis and care. As a result, there is a need for affordable testing solutions to ensure wider accessibility and adoption across diverse healthcare systems, which remains a challenge in the market's development.

• Limited awareness in low-resource regions

A significant challenge for the preeclampsia laboratory testing market is the limited awareness and access to diagnostic testing, particularly in low- and middle-income regions. In many developing countries, healthcare infrastructure may be inadequate to support the widespread use of advanced testing methods, and there may be limited knowledge about the importance of early detection and diagnosis of preeclampsia. This lack of awareness can lead to delayed diagnoses, with pregnant women in these regions at higher risk of complications from untreated preeclampsia. Increasing education, awareness, and access to diagnostic tools is essential to overcoming this challenge and improving maternal health outcomes globally.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Preeclampsia Laboratory Testing Market Scope

The market is segmented on the basis of product, test, and end user growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Instruments

Test

• Blood test
• Urine test
• Others

End User

• Hospitals
• Clinics
• Diagnostic Center
• Other

Preeclampsia Laboratory Testing Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, test, and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America is the dominating region in the preeclampsia laboratory testing market, primarily due to its advanced healthcare infrastructure, technological advancements, and high healthcare spending. The region is home to numerous hospitals and healthcare facilities equipped with state-of-the-art diagnostic tools, allowing for effective and early detection of preeclampsia. The high demand for accurate, efficient testing methods is also supported by the growing awareness of maternal health, as well as increasing governmental and institutional focus on improving pregnancy outcomes. Furthermore, the strong presence of key market players in North America ensures continuous innovation and availability of advanced diagnostic tests. The combination of excellent healthcare facilities, high awareness, and continuous innovation makes North America the market leader, with substantial growth in the adoption of both traditional and point-of-care testing methods for preeclampsia.

Asia-Pacific, on the other hand, is the fastest-growing region in the preeclampsia laboratory testing market, driven by a combination of factors including rapid economic growth, increased healthcare investment, and rising awareness about maternal health. Countries such as China, India, and Japan are witnessing a transformation in their healthcare systems, resulting in greater access to advanced diagnostic tools. The region is experiencing a rising demand for improved healthcare solutions, particularly in maternal care. With improvements in medical technology and an increasing focus on maternal health education, more pregnant women are seeking early and accurate diagnosis of preeclampsia. In addition, the expanding middle-class population in these countries is contributing to higher healthcare spending, allowing more women to access advanced laboratory testing. This dynamic, coupled with growing healthcare infrastructure, positions Asia-Pacific as the fastest-growing market for preeclampsia laboratory testing in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Preeclampsia Laboratory Testing Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Preeclampsia Laboratory Testing Market Leaders Operating in the Market Are:

• Siemens (Germany)
• Hologic, Inc. (U.S.)
• Abbott (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• NeuroLogica Corp (U.S.)
• Shimadzu Corporation (Japan)
• BIOMÉRIEUX (France)
• Carestream Health (U.S.)
• MedGyn Products, Inc. (U.S.)
• URIT MEDICAL ELECTRONIC CO., LTD (China)
• Cook (U.S.)
• Cardinal Health. (U.S.)
• PerkinElmer (U.S.)
• GE HealthCare (U.S.)
• Quest Diagnostics Incorporated (U.S.)

Latest Developments in Preeclampsia Laboratory Testing Market

• In January 2024 – Labcorp has launched a new test designed for the risk assessment and prognosis of severe preeclampsia. This test will allow healthcare providers to better assess a pregnant woman’s risk of developing severe preeclampsia, a potentially life-threatening condition. By using a combination of advanced biomarkers, the test offers more accurate predictions, enabling earlier intervention and improved management of the condition. This launch aims to enhance maternal health outcomes by providing more precise, timely data, reducing complications for both mothers and babies, and allowing for personalized care strategies in managing preeclampsia
• In January 2024, Mayo Clinic Laboratories has released a new first-to-market pregnancy risk assessment test in the U.S. The test is designed to evaluate the risk of preeclampsia, a serious pregnancy complication. By analyzing biomarkers associated with preeclampsia, this test provides healthcare providers with a more accurate understanding of a patient's risk level early in the pregnancy. This breakthrough enables better decision-making and the ability to take preventive measures, ultimately improving maternal and fetal outcomes by facilitating earlier interventions and more personalized care
• In July 2023, The U.S. Food and Drug Administration (FDA) approved a new blood test for diagnosing preeclampsia. This test provides healthcare professionals with a reliable tool to detect preeclampsia in pregnant women earlier in their pregnancies. By measuring specific biomarkers, the test helps assess the risk of developing this serious condition, which can lead to complications for both the mother and baby. The approval of this test allows for more timely intervention, improving outcomes by enabling early management and treatment of preeclampsia, ultimately enhancing the safety of both mothers and infants

SKU-66442